References
- Ma S, Lin YY, He J, Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. J COPD 2013; in press.
- Stone PJ, Morris LA, Franzblau C, Snider GL. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1 antitrypsin-deficient humans. Respiration 1995; 62:76–79.
- Gottlieb DJ, Luisetti M, Stone PJ, Short-term supplementation therapy does not affect elastin degradation in severe alpha-1 antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med 2000; 162:2069–2072.
- Stoller JK, Fouhani F, Brantly M, Biochemical efficacy and safety of a new polled human plasma alpha-1 antitrypsin, Respitin. Chest 2002; 122:66–74.
- Fregonese L, Ferrari F, Fumagalli F, Long-term variability of desmosine/isodesmosine as biomarker with alpha-1 antitrypsin deficiency related COPD. J COPD 2011; 8:329–333.
- Vestbo J, Anderson W, Coxson HO, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31:869–873.
- Dirksen A, Piitulainen E, Parr DG, Exploring the role of CT densitometry: A randomised study of augmentation therapy in α1-antitrypsin deficiency. Eur Respir J 2009; 33:1345–1353.
- Chapman KR, Burdon JGW, Piitulainen E, IV alpha- antitrypsin (A1AT) preserves lung density in homozygous alpha-1 antitrypsin deficiency (A1ATD); A randomized, placebo-controlled trial. Am J Respir Crit Care Med 2013; 187:A6069.
- Strange C. The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency (QUANTUM-1). www.ClinicalTrials.gov. ClinicalTrials.gov Identifier NCT 00532805. Accessed May 11, 2013.